U.S. Markets closed

Immunic Stock Jumps As FDA Signs Off On 2 Clinical Trial Applications

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has signed off Immunic Inc's (NASDAQ: IMUX) investigational new drug application for the Phase 3 ENSURE program of lead asset IMU-838 in patients with relapsing-remitting multiple sclerosis.

  • In addition, the FDA also gave a green signal to the company's separate IND application for the supportive Phase 2 CALLIPER trial of IMU-838 in patients with progressive multiple sclerosis (PMS).

  • The ENSURE program comprises two Phase 3 trials designed to evaluate the efficacy, safety, and tolerability of IMU-838 versus placebo in RRMS patients.

  • The Phase 2 CALLIPER trial is intended to run concurrently and complement the Phase 3 program in RRMS.

  • In particular, CALLIPER is focused on progressive forms of multiple sclerosis and designed to corroborate IMU-838's neuroprotective potential, as exemplified by slowing of brain atrophy and delay in disability worsening.

  • Dosing in the ENSURE trials will start in the second half of 2021.

  • The CALLIPER trial is expected to enroll approximately 450 patients, and dosing will commence in the third quarter of 2021.

  • IMUX Price Action: IMUX shares were trading 1.63% higher at $12.46 at last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.